Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Clinical immunology

Understanding Immunodeficiency 99 (IMD99)

At a Glance

IMD99 is an ultra-rare genetic immune disorder that can cause low antibody levels, increasing infection risk, while the immune system attacks blood cells and causes low counts. Care is individualized and may include antibody replacement, medicines to calm immune attacks, and regular blood tests.

Receiving a diagnosis like Immunodeficiency 99 (IMD99) can feel overwhelming, especially because it is an “ultra-rare” condition. In the medical world, “ultra-rare” definitions vary by jurisdiction and organization, but it generally means that only a very small number of people across the globe share this specific genetic profile [1]. While the name is complex, it describes a specific set of challenges your immune system is facing.

This diagnosis is a type of Inborn Error of Immunity (IEI)—a group of conditions where a change in your genetic code affects how your immune system is built or how it functions [2]. Understanding the terms in your diagnosis is the first step toward managing it effectively.

Decoding the Name

The full name of this condition is “Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias.” To understand it, we can break it down into three parts:

  • Hypogammaglobulinemia: This means you have low levels of immunoglobulins (also called antibodies). Antibodies are the “search-and-destroy” proteins your immune system uses to identify and fight off bacteria and viruses [3]. When these levels are low, you are more susceptible to infections, particularly in the lungs, sinuses, and ears [4].
  • Autoimmune: This describes a situation where the immune system mistakenly identifies your own healthy cells as “foreign” and attacks them [5].
  • Cytopenias: This is a general term for low blood cell counts. In immune dysregulation, the immune system may attack your red blood cells (causing autoimmune hemolytic anemia and fatigue), your platelets (causing immune thrombocytopenia, which leads to easy bruising or bleeding), or your white blood cells (causing autoimmune neutropenia, which further increases infection risk) [6][2]. Note: The affected cell line, severity, and cause of a cytopenia vary by person and require laboratory confirmation. Not every person with IMD99 will experience all of these, and your doctor must also acknowledge and rule out nonimmune causes such as infection, medication, bleeding, marrow disease, or hypersplenism.

The Paradox of Immune Dysregulation

It may seem confusing that your immune system can be “weak” (not making enough antibodies) and “overactive” (attacking your own blood cells) at the same time. Doctors call this the immune dysregulation paradox [7].

Think of the immune system like a security team. In IMD99, the team is missing its specialized guards (the antibodies) who recognize outside intruders. At the same time, the remaining guards have become confused and are attacking the building they are supposed to protect (your blood cells) [2]. This happens because the genetic “instruction manual” for the immune system is slightly different, leading to errors in how immune cells mature and how they decide what is a threat [8][9].

The Emotional Journey of an Ultra-Rare Diagnosis

Living with an ultra-rare condition brings a unique set of emotional and psychological challenges. Patients with rare immunodeficiencies may experience:

  • Diagnostic Fatigue: Many patients spend years visiting different specialists before finally receiving an accurate genetic answer [10]. This can lead to a sense of exhaustion and frustration with the medical system [10].
  • Isolation and Uncertainty: Because so few people have this condition, it can be hard to find others who truly understand your experience. You may also feel uncertain about what the future holds, as there is often less long-term data available for ultra-rare conditions compared to common ones [1][11].
  • Quality of Life Impacts: Managing both infections and autoimmune issues can disrupt your work, education, and social life [12][13]. It is common to feel higher levels of anxiety or stress as you balance frequent lab tests and treatments [14][15].

Acknowledging these feelings is a vital part of your care. Your medical team isn’t just there to treat your lab numbers; they are there to help you navigate the impact this diagnosis has on your whole life.

Managing Your Care

Because IMD99 is so rare, there is no “one-size-fits-all” treatment. Instead, care is tailored to how the condition affects you specifically.

  1. Protecting Against Infection: If your infection burden is high and antibody responses are impaired, your doctor may recommend Immunoglobulin Replacement Therapy (IgRT) [3]. This involves receiving antibodies collected from healthy donors, either through a vein (IVIG) or under the skin (SCIG) [16]. IgRT decisions generally consider infection burden, functional antibody responses, the specific diagnosis, and secondary causes, rather than low IgG alone.
  2. Calming the Overactive System: If your immune system is attacking your blood cells, you may need medications that “quiet” that specific response. This can include steroids or more targeted immunosuppressant drugs [17].
  3. Regular Monitoring: You will likely need frequent blood tests to check your “trough” (baseline) antibody levels and to ensure your blood cell counts (red cells, white cells, and platelets) remain in a healthy range [18][2]. Monitoring is highly individualized.

Your role in this process is to be the expert on your own symptoms. By tracking how you feel and staying in close contact with your immunology and hematology team, you can help them adjust your care to find the best possible balance for your immune system.

Common questions in this guide

What is Immunodeficiency 99 (IMD99)?
IMD99 is a very rare genetic immune disorder and an inborn error of immunity. It can lead to low antibody levels, which raise infection risk, while immune system errors can cause attacks on blood cells and low blood counts.
How can IMD99 make the immune system both weak and overactive?
Low antibody levels make it harder to recognize and fight some infections. At the same time, immune cells may mistakenly attack the body's own red blood cells, platelets, or white blood cells.
What do autoimmune cytopenias mean in IMD99?
Autoimmune cytopenias are low blood cell counts caused by immune attacks. Depending on the cell affected, they may cause low red blood cells and fatigue, easy bruising or bleeding, or a higher risk of infection. Laboratory testing is needed, and clinicians also consider nonimmune causes.
Will I need IVIG or SCIG for IMD99?
Some people with IMD99 may be offered immunoglobulin replacement through a vein (IVIG) or under the skin (SCIG) when infections are a problem and antibody responses are impaired. The decision depends on infection history, functional antibody responses, diagnosis, and possible secondary causes, not a low IgG level alone.
How is IMD99 monitored over time?
Monitoring is individualized and may include blood tests for antibody levels between treatments and counts of red cells, white cells, and platelets. Clinicians use these results along with symptoms and infections to adjust care.
Which specialists should be involved in IMD99 care?
An immunology team can address antibody deficiency and infection prevention, while hematology can evaluate low blood counts and autoimmune attacks. Medical genetics can help interpret the gene change and inheritance pattern, and the specialists may coordinate the plan.

Get notified when new evidence is published on immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS).

    Hitchcock I, Skrobanski H, Matter E, et al.

    Orphanet journal of rare diseases 2024; (19(1)):203 doi:10.1186/s13023-024-03215-9.

    PMID: 38760658
  2. 2

    Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.

    Westermann-Clark E, Meehan CA, Meyer AK, et al.

    Frontiers in immunology 2021; (12()):649182 doi:10.3389/fimmu.2021.649182.

    PMID: 33968040
  3. 3

    Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.

    Pecoraro A, Crescenzi L, Granata F, et al.

    International immunopharmacology 2017; (52()):136-142 doi:10.1016/j.intimp.2017.09.005.

    PMID: 28898770
  4. 4

    Infections in Disorders of Immune Regulation.

    Thangaraj A, Tyagi R, Suri D, Gupta S

    Pathogens (Basel, Switzerland) 2024; (13(3)) doi:10.3390/pathogens13030259.

    PMID: 38535602
  5. 5

    Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.

    Cortesi M, Soresina A, Dotta L, et al.

    Frontiers in immunology 2022; (13()):846660 doi:10.3389/fimmu.2022.846660.

    PMID: 35464467
  6. 6

    Immune cytopenias as a continuum in inborn errors of immunity: An in-depth clinical and immunological exploration.

    Zama D, Conti F, Moratti M, et al.

    Immunity, inflammation and disease 2021; (9(2)):583-594 doi:10.1002/iid3.420.

    PMID: 33838017
  7. 7

    Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study.

    Tsilifis C, Speckmann C, Lum SH, et al.

    The Journal of allergy and clinical immunology 2024; (154(6)):1534-1544 doi:10.1016/j.jaci.2024.08.020.

    PMID: 39218359
  8. 8

    NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.

    Boztug H, Hirschmugl T, Holter W, et al.

    Journal of clinical immunology 2016; (36(6)):533-40 doi:10.1007/s10875-016-0306-1.

    PMID: 27338827
  9. 9

    Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.

    Tuijnenburg P, Lango Allen H, Burns SO, et al.

    The Journal of allergy and clinical immunology 2018; (142(4)):1285-1296 doi:10.1016/j.jaci.2018.01.039.

    PMID: 29477724
  10. 10

    Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

    Wolf HM, Candotti F, Spelsberg R, et al.

    Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.

    PMID: 41859081
  11. 11

    The burden of severe leukocyte adhesion deficiency, type I (LAD-I): A multiple-case study from the caregiver's perspective.

    O'Connor M, Simas C, Keith M, et al.

    Journal of human immunity 2026; (2(4)):e20260022 doi:10.70962/jhi.20260022.

    PMID: 42254725
  12. 12

    Inborn errors of immunity at school: How can we do better?

    Lopez-Seguer L, Rodriguez-Tello S, Gonzalez-Amores M, et al.

    Journal of human immunity 2026; (2(3)):e20250120 doi:10.70962/jhi.20250120.

    PMID: 42170002
  13. 13

    Work participation in inborn errors of immunity: The dual burden on patients and caregivers.

    Pulvirenti F, Sgrulletti M, Radovic K, et al.

    Journal of human immunity 2026; (2(6)) doi:10.70962/jhi.20260077.

    PMID: 42911122
  14. 14

    Psychological Symptoms in Patients with Inborn Errors of Immunity and Their Family Members: A Cross-Sectional Study.

    Alpagat G, Nas N

    Medicina (Kaunas, Lithuania) 2026; (62(8)) doi:10.3390/medicina62081616.

    PMID: 42654513
  15. 15

    Health-Related Quality of Life and Emotional Health in X-Linked Carriers of Chronic Granulomatous Disease in the United Kingdom.

    Battersby AC, Braggins H, Pearce MS, et al.

    Journal of clinical immunology 2019; (39(2)):195-199 doi:10.1007/s10875-019-00607-6.

    PMID: 30868346
  16. 16

    Immunoglobulin therapy for immunodeficiency.

    Wilson BE, Freeman CM

    Allergy and asthma proceedings 2024; (45(5)):364-370 doi:10.2500/aap.2024.45.240053.

    PMID: 39294913
  17. 17

    Immunosuppressive therapy with rituximab in common variable immunodeficiency.

    Pecoraro A, Crescenzi L, Galdiero MR, et al.

    Clinical and molecular allergy : CMA 2019; (17()):9 doi:10.1186/s12948-019-0113-3.

    PMID: 31080365
  18. 18

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910

This page is for informational purposes only and does not constitute medical advice. Your immunologist, hematologist, and genetics team should interpret your genetic report, blood counts, infection history, and treatment options.